BACKGROUND: Some regimens of chemotherapy cause peripheral neuropathy such as pain in muscles and joints and numbness in the limbs. It is often difficult to estimate the neuropathy accurately and analyze it in detail. The aim of this study was to investigate whether chemotherapy-induced peripheral neuropathy could be appropriately estimated by using the visual analogue scale (VAS). METHODS: Ninety-three patients who received paclitaxel and carboplatin treatment (TC) or paclitaxel and docetaxel treatment (DC) participated in answering a questionnaire about peripheral neuropathy using the VAS. As a result, 134 cycles of TC and 79 cycles of DC were evaluated. The average of VAS scores at every 10 days after each cycle of chemotherapy began was calculated. The daily change in VAS scores was also analyzed, and average VAS scores compared between TC and DC. RESULTS: Daily changes in peripheral neuropathy for each treatment could be demonstrated in detail. Pain and numbness had separate patterns of appearance. For both pain and numbness, a greater VAS score was observed in patients receiving TC than in those receiving DC. As the number of cycles grew, peripheral neuropathy became more serious in TC. CONCLUSIONS: The VAS could appropriately recognize the difference in peripheral neuropathy between TC and DC. Moreover, the VAS could also catch the change in peripheral neuropathy. This result suggests that the VAS system is a useful tool for managing peripheral neuropathy.
BACKGROUND: Some regimens of chemotherapy cause peripheral neuropathy such as pain in muscles and joints and numbness in the limbs. It is often difficult to estimate the neuropathy accurately and analyze it in detail. The aim of this study was to investigate whether chemotherapy-induced peripheral neuropathy could be appropriately estimated by using the visual analogue scale (VAS). METHODS: Ninety-three patients who received paclitaxel and carboplatin treatment (TC) or paclitaxel and docetaxel treatment (DC) participated in answering a questionnaire about peripheral neuropathy using the VAS. As a result, 134 cycles of TC and 79 cycles of DC were evaluated. The average of VAS scores at every 10 days after each cycle of chemotherapy began was calculated. The daily change in VAS scores was also analyzed, and average VAS scores compared between TC and DC. RESULTS: Daily changes in peripheral neuropathy for each treatment could be demonstrated in detail. Pain and numbness had separate patterns of appearance. For both pain and numbness, a greater VAS score was observed in patients receiving TC than in those receiving DC. As the number of cycles grew, peripheral neuropathy became more serious in TC. CONCLUSIONS: The VAS could appropriately recognize the difference in peripheral neuropathy between TC and DC. Moreover, the VAS could also catch the change in peripheral neuropathy. This result suggests that the VAS system is a useful tool for managing peripheral neuropathy.
Authors: S E Jones; J Erban; B Overmoyer; G T Budd; L Hutchins; E Lower; L Laufman; S Sundaram; W J Urba; K I Pritchard; R Mennel; D Richards; S Olsen; M L Meyers; P M Ravdin Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Peter S Creticos; John T Schroeder; Robert G Hamilton; Susan L Balcer-Whaley; Arouna P Khattignavong; Robert Lindblad; Henry Li; Robert Coffman; Vicki Seyfert; Joseph J Eiden; David Broide Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: G Cavaletti; G Bogliun; L Marzorati; A Zincone; M Piatti; N Colombo; D Franchi; M T La Presa; A Lissoni; A Buda; F Fei; S Cundari; C Zanna Journal: Ann Oncol Date: 2004-09 Impact factor: 32.976
Authors: Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye Journal: J Natl Cancer Inst Date: 2004-11-17 Impact factor: 13.506
Authors: Sandro Pignata; Sabino De Placido; Rosalbino Biamonte; Giovanni Scambia; Giovanni Di Vagno; Giuseppe Colucci; Antonio Febbraro; Marco Marinaccio; Alessandra Vernaglia Lombardi; Luigi Manzione; Giacomo Cartenì; Mario Nardi; Saverio Danese; Maria Rosaria Valerio; Andrea de Matteis; Bruno Massidda; Giampietro Gasparini; Massimo Di Maio; Carmela Pisano; Francesco Perrone Journal: BMC Cancer Date: 2006-01-07 Impact factor: 4.430
Authors: Tiffany Li; Susanna B Park; Eva Battaglini; Madeleine T King; Matthew C Kiernan; David Goldstein; Claudia Rutherford Journal: Qual Life Res Date: 2022-05-21 Impact factor: 3.440
Authors: Daniel L Hertz; Kouros Owzar; Sherrie Lessans; Claudia Wing; Chen Jiang; William Kevin Kelly; Jai Patel; Susan Halabi; Yoichi Furukawa; Heather E Wheeler; Alexander B Sibley; Cameron Lassiter; Lois Weisman; Dorothy Watson; Stefanie D Krens; Flora Mulkey; Cynthia L Renn; Eric J Small; Phillip G Febbo; Ivo Shterev; Deanna L Kroetz; Paula N Friedman; John F Mahoney; Michael A Carducci; Michael J Kelley; Yusuke Nakamura; Michiaki Kubo; Susan G Dorsey; M Eileen Dolan; Michael J Morris; Mark J Ratain; Howard L McLeod Journal: Clin Cancer Res Date: 2016-05-03 Impact factor: 12.531